- Home
- SLSN vs ESPR Comparison
SLSN vs ESPR Comparison
Compare SLSN & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLSN
- ESPR
- Stock Information
- Founded
- SLSN 1989
- ESPR 2008
- Country
- SLSN United States
- ESPR United States
- Employees
- SLSN N/A
- ESPR N/A
- Industry
- SLSN
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- SLSN
- ESPR Health Care
- Exchange
- SLSN NYSE
- ESPR Nasdaq
- Market Cap
- SLSN 270.6M
- ESPR 220.0M
- IPO Year
- SLSN N/A
- ESPR 2013
- Fundamental
- Price
- SLSN $2.78
- ESPR $1.40
- Analyst Decision
- SLSN
- ESPR Buy
- Analyst Count
- SLSN 0
- ESPR 6
- Target Price
- SLSN N/A
- ESPR $6.50
- AVG Volume (30 Days)
- SLSN 74.6K
- ESPR 5.1M
- Earning Date
- SLSN 07-31-2025
- ESPR 08-05-2025
- Dividend Yield
- SLSN N/A
- ESPR N/A
- EPS Growth
- SLSN N/A
- ESPR N/A
- EPS
- SLSN 0.07
- ESPR N/A
- Revenue
- SLSN $64,417,000.00
- ESPR $259,574,000.00
- Revenue This Year
- SLSN N/A
- ESPR $6.10
- Revenue Next Year
- SLSN N/A
- ESPR N/A
- P/E Ratio
- SLSN $45.92
- ESPR N/A
- Revenue Growth
- SLSN 65.67
- ESPR 12.99
- 52 Week Low
- SLSN $1.21
- ESPR $0.69
- 52 Week High
- SLSN $16.56
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- SLSN N/A
- ESPR 58.85
- Support Level
- SLSN N/A
- ESPR $1.13
- Resistance Level
- SLSN N/A
- ESPR $1.74
- Average True Range (ATR)
- SLSN 0.00
- ESPR 0.17
- MACD
- SLSN 0.00
- ESPR 0.01
- Stochastic Oscillator
- SLSN 0.00
- ESPR 30.61
About SLSN SOLESENCE INC
Solesence Inc is a scientifically driven health care solutions company across beauty and life science categories, protecting skin from environmental aggressors and enhancing the aesthetic appeal of healthy products. The group is engaged in the beauty category that develops and manufactures clean, inclusive, mineral-based skincare and makeup products at the forefront of skin health. Its brands are Stress Defense, Kleair, and Bloom.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.